Malta - İngilizce - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - human plasma, protein - solution for infusion or injection - human plasma protein 50 mg/ml - immune sera and immunoglobulins

İsrail - İngilizce - Ministry of Health

kamada ltd, israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 100 mg/ml - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents (0-18 years) in: - primary immunodeficiency syndromes (pid) with impaired antibody production - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of <4 g/l * psaf= failure to mount at least a 2-fold rise in igg antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccinesimmunomodulation in adults, and children and adolescents (0-18 years) in: - primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count - guillain barré syndrome - kawasaki disease (in conjunction with acetylsalicylic acid) - chronic inflammatory demyelinating polyradiculoneuropathy (cidp) - multifocal motor neuropathy (mmn)

Malta - İngilizce - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - human hepatitis, b immunoglobulin, human plasma, protein - solution for injection - human hepatitis b immunoglobulin 200 iu human plasma protein 100-170 mg - immune sera and immunoglobulins

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human plasma protein >90% gamma globulin - solution for injection - 1.6g/10ml %w/v

Singapur - İngilizce - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - immunoglobulin (polyvalent) (human) - injection - 160 mg/ml - immunoglobulin (polyvalent) (human) 160 mg/ml

Singapur - İngilizce - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human normal immunoglobulin (human plasma protein containing at least 96% immunoglobulin) - infusion, solution - 50 mg/ml - human normal immunoglobulin (human plasma protein containing at least 96% immunoglobulin) 50 mg/ml

Malta - İngilizce - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - immunoglobulin antihepatitis - solution for injection - immunoglobulin antihepatitis b 100 iu/ml - immune sera and immunoglobulins

Kenya - İngilizce - Pharmacy and Poisons Board

human bioplazma llc h-2100 godollo transics milhaly ut 80hungary - human albumin - solution for infusion - 20%human albumin - blood substitutes and plasma protein fractions

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for injection

ABD - İngilizce - NLM (National Library of Medicine)

biogen inc. - (1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) (unii: 7pcm518ylr) ((1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) - unii:7pcm51 - (1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) 250 [iu] in 3 ml - eloctate, antihemophilic factor (recombinant), fc fusion protein, is a recombinant dna derived, antihemophilic factor indicated in adults and children with hemophilia a (congenital factor viii deficiency) for: - on-demand treatment and control of bleeding episodes, - perioperative management of bleeding, - routine prophylaxis to reduce the frequency of bleeding episodes. limitation of use eloctate is not indicated for the treatment of von willebrand disease. eloctate is contraindicated in patients who have had life-threatening hypersensitivity reactions to eloctate or other constituents of the product. [see description (11 )] risk summary there are no studies of eloctate use in pregnant women to inform a drug-associated risk. the background risk of major birth defects and miscarriage in the indicated population is unknown; however, the background risk of major birth defects in the u.s. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. animal reproductive and devel